Published in J Neurooncol on September 22, 2011
Targeting the PDGF signaling pathway in tumor treatment. Cell Commun Signal (2013) 1.45
Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro Oncol (2014) 1.19
Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol (2014) 1.03
Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol (2012) 1.00
Activation of abl family kinases in solid tumors. Genes Cancer (2012) 0.89
Expression of proto-oncogene KIT is up-regulated in subset of human meningiomas. BMC Cancer (2012) 0.80
Expression of CD163 prevents apoptosis through the production of granulocyte colony-stimulating factor in meningioma. Neuro Oncol (2013) 0.80
Re-evaluation of cytostatic therapies for meningiomas in vitro. J Cancer Res Clin Oncol (2014) 0.79
Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake. Neuro Oncol (2016) 0.75
A case of recurrent anaplastic meningioma of the skull base with radiologic response to hydroxyurea. J Neurol Surg Rep (2014) 0.75
Imatinib mesylate plus hydroxyurea chemotherapy for cerebellar meningioma in a Belgian Malinois dog. J Vet Med Sci (2014) 0.75
Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. J Clin Oncol (2015) 0.75
Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol (1990) 18.71
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res (2006) 2.44
Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol (2006) 2.33
Pathological classification and molecular genetics of meningiomas. J Neurooncol (2010) 2.03
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol (2005) 1.85
Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J Neurosurg (1997) 1.74
Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation. Neurosurgery (2009) 1.47
Malignant progression in meningioma: documentation of a series and analysis of cytogenetic findings. J Neurosurg (2004) 1.33
Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol (2009) 1.30
Temozolomide for treatment-resistant recurrent meningioma. Neurology (2004) 1.23
Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol (2009) 1.21
Intracranial meningiomas of atypical (WHO grade II) histology. J Neurooncol (2010) 1.14
Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma. Neuro Oncol (2011) 1.14
Salvage chemotherapy with CPT-11 for recurrent meningioma. J Neurooncol (2006) 1.08
Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest (2006) 1.03
Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg (2002) 1.03
A review of malignant meningiomas: diagnosis, characteristics, and treatment. J Neurooncol (2010) 1.02
Prolonged oral hydroxyurea and concurrent 3d-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study. J Neurooncol (2005) 0.99
Hydroxyurea chemotherapy for unresectable or residual meningioma. J Neurooncol (2000) 0.96
Hydroxyurea chemotherapy in the treatment of meningiomas. Neurosurg Focus (2007) 0.95
Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas. Cancer (2008) 0.93
Evidence for mitogen-associated protein kinase activation and transduction of mitogenic signals by platelet-derived growth factor in human meningioma cells. J Neurosurg (2001) 0.93
Platelet-derived growth factor expression and stimulation in human meningiomas. J Neurosurg (1994) 0.91
Aberrant signaling pathways in meningiomas. J Neurooncol (2010) 0.91
Human meningiomas co-express platelet-derived growth factor (PDGF) and PDGF-receptor genes and their protein products. Int J Cancer (1990) 0.90
Non-resectable slow-growing meningiomas treated by hydroxyurea. J Neurooncol (2004) 0.89
Autocrine growth stimulation of human meningioma cells by platelet-derived growth factor. J Neurosurg (1996) 0.88
Different distribution of c-myc and MIB-1 positive cells in malignant meningiomas with reference to TGFs, PDGF, and PgR expression. Brain Tumor Pathol (2001) 0.88
Evidence for phosphatidylinositol 3-kinase-Akt-p7S6K pathway activation and transduction of mitogenic signals by platelet-derived growth factor in meningioma cells. J Neurosurg (2002) 0.88
Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up. Br J Neurosurg (2004) 0.88
Treatment of high risk or recurrent meningiomas with hydroxyurea. J Clin Neurosci (2002) 0.87
Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series. J Neurooncol (2011) 0.86
Expression of PDGF and its receptor as well as their relationship to proliferating activity and apoptosis of meningiomas in human meningiomas. J Clin Neurosci (2001) 0.86
Inhibition of proliferation of human cerebral meningioma cells by suramin: effects on cell growth, cell cycle phases, extracellular growth factors, and PDGF-BB autocrine growth loop. J Neurosurg (1995) 0.84
Mifepristone (RU 486) treatment of meningiomas. J Neurol Neurosurg Psychiatry (1992) 0.82
Platelet-derived growth factor (PDGF) and receptor (PDGFR) expression in human meningiomas: correlations with clinicopathological features and cytogenetic analysis. Neuropathol Appl Neurobiol (1994) 0.81
Expression of PDGF, PDGF-receptor, EGF-receptor and sex hormone receptors on meningioma. Acta Neurochir (Wien) (1994) 0.81
Control of meningioma cell growth by platelet-derived growth factor (PDGF). J Neurol Sci (1995) 0.78
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature (2006) 27.91
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol (2009) 14.15
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol (2007) 12.62
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell (2007) 12.52
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res (2007) 9.21
The genetic landscape of the childhood cancer medulloblastoma. Science (2010) 8.34
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88
Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res (2006) 6.77
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol (2010) 6.30
Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell (2009) 5.81
Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin (2010) 5.53
The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer (2007) 5.28
Novel mutations target distinct subgroups of medulloblastoma. Nature (2012) 4.82
Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res (2006) 4.80
Video-assisted thoracic surgery lobectomy: report of CALGB 39802--a prospective, multi-institution feasibility study. J Clin Oncol (2007) 4.42
Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol (2008) 4.39
Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res (2004) 4.26
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol (2003) 3.83
Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell (2010) 3.82
Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. Ann Thorac Surg (2006) 3.76
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol (2006) 3.60
The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle (2009) 3.55
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol (2010) 3.43
Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell (2013) 3.32
Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study. Cancer (2002) 3.23
Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. Cancer Cell (2009) 3.11
Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial. Lancet (2010) 3.07
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res (2006) 3.02
A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res (2009) 3.00
Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol (2007) 2.99
Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res (2008) 2.97
The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet (2013) 2.89
Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncol (2013) 2.82
Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol (2006) 2.82
Positive and negative network correlations in temporal lobe epilepsy. Cereb Cortex (2004) 2.73
Response criteria for glioma. Nat Clin Pract Oncol (2008) 2.69
Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol (2006) 2.69
Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res (2005) 2.63
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov (2012) 2.61
Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol (2006) 2.60
Impact of PhD training on scholarship in a neurosurgical career. J Neurosurg (2013) 2.59
Recent advances in the treatment of malignant astrocytoma. J Clin Oncol (2006) 2.55
A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol (2006) 2.49
Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol (2005) 2.48
c-Myc is required for maintenance of glioma cancer stem cells. PLoS One (2008) 2.41
Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res (2011) 2.40
Bayesian adaptive randomized trial design for patients with recurrent glioblastoma. J Clin Oncol (2012) 2.39
Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid. Cancer Res (2005) 2.35
Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). J Natl Cancer Inst (2006) 2.34
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol (2009) 2.32
Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol (2008) 2.32
Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol (2006) 2.29
Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol (2009) 2.29
EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci Signal (2009) 2.23
Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res (2002) 2.23
Variations in pulmonary venous drainage to the left atrium: implications for radiofrequency ablation. Radiology (2004) 2.21
Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol (2007) 2.20
Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery (2012) 2.19
Estimate of lung cancer mortality from low-dose spiral computed tomography screening trials: implications for current mass screening recommendations. J Clin Oncol (2004) 2.18
Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol (2003) 2.16
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A (2013) 2.14
End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. J Clin Oncol (2009) 2.13
An animal model of MYC-driven medulloblastoma. Cancer Cell (2012) 2.12
Brain cancer stem cells display preferential sensitivity to Akt inhibition. Stem Cells (2008) 2.12
Proteomic and immunologic analyses of brain tumor exosomes. FASEB J (2008) 2.11
Epidemiology of brain metastases. Curr Oncol Rep (2012) 2.09
Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol (2012) 2.08
Long-term adjustment of survivors of early-stage breast carcinoma, 20 years after adjuvant chemotherapy. Cancer (2003) 2.06